

 Open access • Posted Content • DOI:10.1101/2019.12.12.874792

STING controls Herpes Simplex Virus in vivo independent of type I interferon induction

— [Source link](#) 

Lívia H. Yamashiro, Lívia H. Yamashiro, Stephen C. Wilson, Stephen C. Wilson ...+10 more authors

Institutions: Howard Hughes Medical Institute, University of California, Berkeley, Celgene, Helen Wills Neuroscience Institute ...+1 more institutions

Published on: 13 Dec 2019 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: Sting, Stimulator of interferon genes, Interferon and IRF3

Related papers:

- [Interferon-independent STING signaling promotes resistance to HSV-1 in vivo.](#)
- [TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections.](#)
- [Herpes Simplex Virus 1 γ 1 34.5 Protein Inhibits STING Activation That Restricts Viral Replication](#)
- [The function of feline stimulator of interferon gene \(STING\) is evolutionarily conserved](#)
- [The herpesviral antagonist m152 reveals differential activation of STING-dependent IRF and NF-κB signaling and STING's dual role during MCMV infection.](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/sting-controls-herpes-simplex-virus-in-vivo-independent-of-5aaoklxnvr>

STING controls Herpes Simplex Virus *in vivo* independent of type I interferon induction

Lívia H. Yamashiro^{1,2}, Stephen C. Wilson^{1,3}, Huntly M. Morrison¹, Vasiliki Karalis⁴,
Jing-Yi J. Chung¹, Katherine J. Chen¹, Helen S. Bateup^{4,5,6}, Moriah L. Szpara⁷, Angus Y.
Lee⁸, Jeffery S. Cox^{1,9}, Russell E. Vance^{1,2,8,9*}

¹ Division of Immunology and Pathogenesis, Department of Molecular and Cell Biology,
University of California, Berkeley, CA 94720 USA

² Howard Hughes Medical Institute, University of California, Berkeley, CA 94720 USA

³ Current Address: Celgene Corporation, 200 Cambridge park Dr, Cambridge, MA 02140

⁴ Division of Neurobiology, Department of Molecular and Cell Biology, University of
California, Berkeley, CA 94720 USA

⁵ Helen Wills Neuroscience Institute, University of California, Berkeley, CA 94720 USA

⁶ Chan Zuckerberg Biohub, San Francisco, CA 94158 USA

⁷ Department of Biochemistry and Molecular Biology, Center for Infectious Disease
Dynamics, Huck Institutes of the Life Sciences, Pennsylvania State University,
University Park, PA 16801 USA

⁸ Cancer Research Laboratory, University of California, Berkeley, CA 94720 USA

⁹ Henry Wheeler Center for Emerging and Neglected Diseases, University of California,
Berkeley, CA 94720 USA

* e-mail: rvance@berkeley.edu

Abstract

The Stimulator of Interferon Genes (STING) pathway initiates potent immune responses upon recognition of DNA derived from bacteria, viruses and tumors. To signal, the C-terminal tail (CTT) of STING recruits TBK1, a kinase that phosphorylates serine 365 (S365) in the CTT. Phospho-S365 acts as a docking site for IRF3, a transcription factor that is phosphorylated and activated by TBK1, leading to transcriptional induction of type I interferons (IFNs). IFNs are essential for antiviral immunity and are widely viewed as the primary output of STING signaling in mammals. However, other more evolutionarily ancestral responses, such as induction of NF- κ B or autophagy, also occur downstream of STING. The relative importance of the various outputs of STING signaling during *in vivo* infections is unclear. Here we report that mice harboring a serine 365-to-alanine (S365A) point mutation in STING exhibit normal susceptibility to *Mycobacterium tuberculosis* infection but, unexpectedly, are resistant to Herpes Simplex Virus (HSV)-1, despite lacking STING-induced type I IFN responses. Likewise, we find *Irf3*^{-/-} mice exhibit resistance to HSV-1. By contrast, resistance to HSV-1 is abolished in mice lacking the STING CTT or TBK1, suggesting that STING protects against HSV-1 upon TBK1 recruitment by the STING CTT, independent of IRF3 or type I IFNs. Interestingly, we find that STING-induced autophagy is a TBK1-dependent IRF3-independent process that is conserved in the STING S365A mice, and autophagy has previously been shown to be required for resistance to HSV-1. We thus propose that autophagy and perhaps other ancestral interferon-independent functions of STING are required for STING-dependent antiviral responses *in vivo*.

1 **Introduction**

2 The immune response to pathogens is initiated upon detection of pathogen-
3 associated molecular patterns (PAMPs) such as lipopolysaccharide, flagellin and nucleic
4 acids [1]. Double-stranded DNA (dsDNA) is an important PAMP for the detection of
5 many pathogens, including *Mycobacterium tuberculosis* and Herpes Simplex Virus-1
6 (HSV-1) [2-4]. In vertebrates, the intracellular presence of dsDNA is detected by cyclic-
7 GMP-AMP Synthase (cGAS), a dsDNA-activated enzyme that produces a cyclic
8 dinucleotide (CDN) second messenger called 2'3'-cyclic-GMP-AMP (2'3'cGAMP) [5-
9 10]. 2'3'cGAMP binds and activates the ER-resident transmembrane protein Stimulator
10 of Interferon Genes (STING). Transcriptional induction of type I IFNs is widely
11 presumed to be the primary output of STING signaling during antiviral defense.
12 However, STING is evolutionarily ancient, present even in bacteria [11] and in animals
13 such as the starlet sea anemone *Nematostella vectensis* and *Drosophila melanogaster* that
14 do not appear to encode type I interferons [12]. By contrast, autophagy and NF- κ B
15 signaling are ancestral STING-induced signaling pathways, present in both *N. vectensis*
16 and *D. melanogaster*, raising the possibility that these pathways are the primary or
17 ancestral signaling outputs of STING [13-16].

18 The relative *in vivo* importance of the various signaling outputs of STING for
19 anti-viral immunity in vertebrates is unknown. To address this issue, we used
20 CRISPR/Cas9 to generate two distinct *Sting* mutant mouse lines: (1) STING S365A
21 mice, which harbor a mutation in *Sting* that results in a serine to alanine substitution at
22 amino acid 365; and (2) STING Δ CTT mice, in which valine 340 has been substituted by
23 a STOP codon, resulting in a STING protein that lacks the entire CTT (Supp. Fig. S1a

24 and S1b). We compared the S365A and Δ CTT mice to our previously generated STING-
25 null *Goldenticket* (*Gt*) mice [17]. Since phosphorylation of S365 in the CTT of STING is
26 required for the recruitment and activation of IRF3 [18-20], we predicted that S365A
27 mice would be deficient in type I IFN responses downstream of STING, but would retain
28 all other STING-dependent signaling events such as autophagy or NF- κ B induction. The
29 STING CTT contains S365 and is also essential for recruitment of TBK1 [21, 22]. Thus,
30 we predicted that Δ CTT mice should also be deficient in all TBK1-dependent responses
31 downstream of STING.

32 In the present study, we found that STING mutations do not affect susceptibility
33 to *M.tuberculosis*, while control of HSV-1 infection requires the STING CTT but,
34 unexpectedly, is largely independent of S365- or IRF3-induced type I IFNs. Control of
35 HSV-1 also required TBK1, suggesting that STING protects against HSV-1 upon TBK1
36 recruitment by the STING CTT, independent of IRF3 or type I IFNs. We found that
37 STING-induced autophagy is a TBK1-dependent IRF3-independent process that is
38 conserved in the STING S365A mice. Thus, our data provide *in vivo* support for the idea
39 that autophagy induction and perhaps other ancestral interferon-independent functions of
40 STING may be preserved in vertebrates for host defense.

41

42 **Results**

43 **Defective type I IFN induction in STING S365A and Δ CTT macrophages.**

44 Prior studies identified serine 365 of mouse STING (S366 in human STING) to
45 be essential for STING-induced type I IFN expression in transfected or transduced cells
46 *in vitro* [18-20]. To test whether endogenous STING requires the CTT and S365 for IFN

47 induction in primary cells, bone marrow-derived macrophages from wild-type (WT)
48 C57BL/6J, *Goldenticket* (*Gt*) STING null mice, and STING S365A and Δ CTT mice were
49 stimulated with STING-specific agonists, including CDNs such as c-di-GMP and
50 2'3'cGAMP, as well as the cGAS agonist, dsDNA. As controls, cells were also stimulated
51 with Sendai virus (SeV) and poly I:C, which induce type I IFNs via the RIG-I–MAVS
52 pathway, independently of cGAS–STING. As expected, stimulation with STING-specific
53 agonists resulted in increased *Ifnb* expression only in WT cells and not in any of the
54 STING mutant cells. By contrast, the IFN response of all four genotypes was similar in
55 response to SeV and poly I:C (Fig. 1a). STING activation can also lead to production of
56 NF- κ B-induced cytokines, such as TNF- α or IL-6 [23, 24]. Interestingly, primary *Gt*,
57 S365A and Δ CTT macrophages stimulated *in vitro* with CDNs or dsDNA were defective
58 for TNF- α induction as compared to WT cells (Supp. Fig. 1c). However, *in vivo*
59 stimulation with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a potent STING
60 agonist [25, 26], resulted in measurable TNF- α responses in the serum of WT and
61 STING S365A mice, whereas *Gt* and Δ CTT mice were defective in TNF- α production as
62 expected (Fig. 1b). As a control, the TNF- α response to STING-independent stimuli (e.g.,
63 LPS, which activates NF- κ B via TLR4) was normal in all genotypes (Fig. 1b). We
64 conclude that S365 may play a role in NF- κ B activation, at least in macrophages, but is
65 not required for NF- κ B activation *in vivo* in response to strong STING agonists.

66 To further characterize our new STING mutant mice, the expression and/or
67 activation of STING and downstream signaling components was assessed by
68 immunoblotting (Fig. 1c). The STING S365A mutation did not affect expression of the
69 STING protein itself or downstream components such as TBK1 and IRF3. STING Δ CTT

70 mice harbor a STING protein of the expected (decreased) molecular weight.
71 Phosphorylation of TBK1—but not of STING or IRF3—occurred in S365A cells in
72 response to STING agonist, consistent with the generally accepted requirement for S365
73 phosphorylation for IRF3 binding and activation (Fig. 1c). By contrast, no
74 phosphorylation of STING, TBK1 or IRF3 was seen in Δ CTT cells, as expected.

75 In addition to its role in IFN-induction, TBK1 has previously been shown to
76 activate autophagy via the phosphorylation of autophagy adaptor proteins such as
77 NDP52, p62 and optineurin [27]. Likewise, STING activation itself is associated with
78 autophagy-like responses [16, 19, 28, 29]. Interestingly, a recent report claimed that
79 STING-induced autophagy does not require the CTT or TBK1 [16]; however, these
80 experiments utilized conditions that may not reflect the true *in vivo* requirements, such as
81 overexpressed proteins, immortalized cell lines, and/or artificial *in vitro* stimulations. In
82 order to investigate whether S365 or the CTT is required for endogenous STING to
83 activate autophagy-like processes, primary macrophages were transfected with
84 2'3'cGAMP and conversion of LC3-B from form I to the lipidated form II was analyzed.
85 Robust LC3-B conversion was observed in WT and S365A cells, while this response was
86 reduced in *Gt* and Δ CTT cells (Fig. 1d and e, Supp. Fig. S1d), indicating that STING-
87 dependent autophagy is independent of S365A-IRF3 activation and type I IFN responses
88 but largely requires the CTT. To confirm this result, we quantified colocalization of LC3
89 puncta and cytosolic DNA. Primary macrophages were transfected for 6h with Cy3-
90 labeled DNA and colocalization with LC3 puncta was quantified by
91 immunofluorescence. STING-deficient *Gt* and Δ CTT cells exhibited poor colocalization
92 of DNA and LC3, whereas WT and S365A cells exhibited robust and indistinguishable

93 DNA–LC3 colocalization (Fig. 1f and Supp. Fig. S1e). Taken together these data indicate
94 that endogenous STING requires S365 for IRF3 recruitment and induction of type I IFNs
95 downstream of STING, whereas the CTT (but not S365) is required for TBK1
96 recruitment and robust autophagy induction. Our new mouse models therefore allow us to
97 genetically separate the IFN- and autophagy-inducing functions of endogenous STING
98 for the first time.


99

100

101

102

103



104

105 **Figure 1. Defective type I IFN induction in STING S365A and ΔCTT macrophages.**
 106 **a**, Bone marrow derived macrophages were stimulated for 6h and relative expression of
 107 IFN-β mRNA was measured. **b**, Mice were injected DMXAA (25 mg/kg, i.p.) or LPS (10
 108 ng, i.v.) and TNF-α production was measured on the serum 2h later. **c**, Primary
 109 macrophages were transfected with dsDNA for 4, 8 or 12h or **d**, 2'3'cGAMP for 6h, and
 110 cell lysates were analyzed by immunoblotting for the indicated proteins. **e**, Quantification
 111 of (d). **f**, Quantification of LC3-DNA colocalization in primary macrophages transfected
 112 with Cy3-DNA for 6h and stained with LC3. Images were analyzed by an automated
 113 pipeline created on Perkin Elmer Harmony software for colocalization quantification (for
 114 more details refer to Methods). Representative results of three independent experiments.
 115 Error bars are SEM. Analyzed with one-way ANOVA and Tukey post-test. *, $p \leq 0.05$;
 116 **, $p \leq 0.005$; ***, $p \leq 0.0001$. ns, not significant.

117 **STING mutant mice exhibit normal susceptibility to *M. tuberculosis* infection.**

118


119 To determine whether STING-induced interferons and autophagy have distinct
120 functions during *in vivo* infection, we first examined infections with the bacterium *M.*
121 *tuberculosis*. Previous reports have suggested that the cGAS–STING pathway detects *M.*
122 *tuberculosis* in macrophages and initiates both a type I IFN response and autophagy-like
123 colocalization of bacteria with LC3 [4, 30-32]. Type I IFNs exacerbate many bacterial
124 infections, including *M. tuberculosis* infection [33-36] whereas autophagy is generally
125 anti-bacterial [37]. Therefore, loss of STING may have counteracting effects that obscure
126 its function; indeed, STING-null *Gt* mice do not exhibit dramatic alterations in
127 susceptibility to *M. tuberculosis* infection [31, 38]. We hypothesized that perhaps STING
128 S365A mice, which are defective for STING-induced type I IFN induction but not for
129 autophagy, might exhibit enhanced resistance to *M. tuberculosis*. Consistent with this
130 hypothesis, *Irf3*^{-/-} mice have previously been reported to be resistant to *M.tuberculosis*
131 [30]. Therefore, we aerosol infected mice harboring WT, *Gt*, S365A, or Δ CTT STING
132 alleles with virulent *M.tuberculosis*. We found that all STING genotypes were similarly
133 susceptible to *M.tuberculosis* with similar survival rates, bacterial burdens in lungs and
134 spleens, and cytokine production (Fig. 2a-l).

135

136

137

138



139

140 **Fig 2. STING mutant mice exhibit normal susceptibility to *M.tuberculosis* infection.**
 141 Mice were aerosol infected with 400 CFU dose of *M. tuberculosis* (Erdman strain) and **a**,
 142 weighed every week. **b**, Survival of infected mice. **c**, Bacterial burden from lungs and **d**,
 143 spleens at 21 and **e-f**, 56 days post infection. **g-l**, Cytokine levels in the lungs from
 144 infected mice at day 21, measured by CBA. Similar (not statistically different among
 145 genotypes) results were observed at day 56 (data not shown). All mice except C57BL/6J
 146 WT were bred in-house. Representative results of five independent experiments. Error
 147 bars are SEM. Analyzed with one-way ANOVA and Tukey post-test. ns, not significant.

148 To confirm that STING-induced type I IFN signaling does not affect *M.*
149 *tuberculosis* susceptibility, we also sought to infect mice lacking the downstream
150 transcription factor, IRF3. However, the published *Irf3*^{-/-} mice that were previously
151 tested are also deficient in *Bcl2l12*, a gene that neighbors *Irf3* and that was inadvertently
152 disrupted by the deletion targeting *Irf3* [39]. Therefore, we generated new *Irf3* deficient
153 (but *Bcl2l12*^{+/+}) mice, as well as *Bcl2l12*^{-/-} (but *Irf3*^{+/+}) mice, using CRISPR–Cas9
154 (Supp. Fig. S2a-S2d). We found *Irf3*^{-/-} mice, *Bcl2l12*^{-/-} mice, and the previously tested
155 doubly deficient mice, were all similarly susceptible to *M.tuberculosis* as WT mice
156 (Supp. Fig. S2e-f). We cannot explain the previously reported resistance of *Irf3*^{-/-} mice
157 but suspect this may be related to microbiota differences between *Irf3*^{-/-} lines.
158 Nevertheless, we conclude that although *M. tuberculosis* can activate cGAS–STING–
159 IRF3 in macrophages *in vitro*, STING does not appear to play significant beneficial or
160 detrimental roles in *M.tuberculosis* pathogenesis *in vivo*.

161


162 **S365A mice are resistant to systemic HSV-1 infection.**

163 Given that STING is essential for resistance to HSV-1, we next decided to
164 challenge our STING mutant mice with HSV-1. *Sting*-deficient mice are highly
165 susceptible to HSV-1 infection [40-42]. Although induction of type I IFN is presumed to
166 be a major mechanism of STING-mediated protection against HSV-1, the relative
167 importance of type I IFNs and other STING-dependent responses in host defense against
168 HSV-1 has not been resolved. Indeed, the immune response to HSV-1 is complex and
169 multi-factorial. HSV-1 encodes factors to block the type I IFN response, perhaps limiting
170 its effectiveness in control of the infection [41, 43, 44]. Moreover, it has been shown that

171 neurons do not require type I IFNs—and can instead rely on autophagy—to limit HSV-1
172 replication in mice *in vivo* and *in vitro* [45]. These observations led us to hypothesize that
173 interferon-independent signaling downstream of STING may contribute to control of
174 HSV-1.

175 Initially, mice were intravenously infected with HSV-1 (KOS strain). As
176 expected, WT mice were resistant to infection and remained healthy through 12 days post
177 infection, whereas STING-deficient *Gt* mice were very susceptible to infection and
178 exhibited rapid weight loss and complete paralysis, succumbing 6 days post infection
179 (Fig. 3a–c) [41]. The Δ CTT mice phenocopied the susceptibility of *Gt* mice,
180 demonstrating that the STING CTT is critical for defense against HSV-1. However, in
181 contrast to Δ CTT mice, the S365A mice unexpectedly showed marked resistance to
182 infection, exhibiting only limited weight loss and paralysis, and recovering fully after 6
183 days of infection (Fig. 3a–c). Susceptibility of *Gt* and Δ CTT mice correlated with
184 elevated viral titers in the brains and spinal cords compared to reduced titers in resistant
185 WT and S365A tissues (Fig. 3d and e). Viral titers among all four genotypes were
186 similarly low in the liver, confirming the neurotropism of HSV-1 (Supp. Fig. S3a). Given
187 that type I IFNs are essential for resistance to HSV-1 [46, 47], and that STING is required
188 for type I IFN induction to HSV-1 [40–42, 48], we were surprised that S365A mice were
189 not as susceptible to infection as *Gt* and Δ CTT mice. One possibility to explain this result
190 is that S365A is not required for STING-dependent type I IFN induction *in vivo*. To test
191 this possibility, we measured expression of *Ifnb* and the interferon stimulated genes
192 (ISGs) *viperin* and *Ifit1* in mice brains following intravenous infection. Only WT brains
193 exhibited a detectable STING-induced IFN response (Fig. 3f and g and Supp. Fig. S3b).

194 In addition, *Tnf* and *Il6* expression was also elevated only in the brains of WT mice
 195 (Supp. Fig. S3c and S3d). These data indicate that S365 is critical for STING-induced
 196 type I IFN and other cytokines, but surprisingly, this S365-induced response is not
 197 critical for STING-dependent immunity to HSV-1.



198


199 **Figure 3. S365A mice are resistant to systemic HSV-1 infection.** Mice were
 200 intravenously infected with 1×10^6 PFU of HSV-1 (KOS strain). **a**, Percentage of initial
 201 weight following infection. **b**, Body condition score (BCS) of infected mice. **c**, Survival
 202 of mice following infection. **d**, Viral titers in the brain and **e**, spinal cord at 6 days p.i. **f**,
 203 Relative expression of *Ifnb* and **g**, *Viperin* in the brain at 3 days p.i. All mice except
 204 C57BL/6J WT were bred in-house. Representative of at least three independent
 205 experiments. Error bars are SEM. Analyzed with one-way ANOVA and Tukey post-test.
 206 *, $p \leq 0.05$; **, $p \leq 0.005$; ***, $p \leq 0.0001$. ns, not significant.

207

208 **S365A mice are resistant to ocular HSV-1 infection.**

209 HSV-1 is a neurotropic virus that is transmitted via mucosal routes (typically oral,
 210 ocular, or genital) and infects epithelial cells before reaching the central nervous system
 211 where it establishes latency in neurons [49, 50]. Therefore, in order to mimic a more
 212 natural route of infection, we challenged mice with HSV-1 using an eye infection model
 213 [41, 51]. In these experiments, we used strain 17, a more virulent HSV-1 isolate, because

214 the KOS strain used for intravenous infections fails to cause pathology in the eye
215 infection model [51]. As with systemic infection, *Gt* and Δ CTT mice rapidly lost weight
216 and all mice succumbed to infection by 6-7 days post infection (Fig. 4a, b). In contrast,
217 WT mice remained fully resistant and S365A mice presented an intermediate phenotype,
218 with initial weight loss but later recovery and ~50% survival (Fig. 4a, b). Similar to
219 systemic infection, the susceptibility of the mice correlated with viral burdens: WT and
220 S365A exhibited lower viral titers in the eye wash (Supp. Fig. S4a), whole brain, brain
221 stem and spinal cord as compared to *Gt* and Δ CTT mice (Fig. 4c-e). Once again, we
222 found that *Ifnb* and *viperin* expression was elevated in WT but not in *Gt*, S365A or Δ CTT
223 brain stems (Fig. 4f and Supp. Fig. S4b). Previous studies have shown that STING-
224 dependent control of HSV-1 is cell-type specific [41]. To investigate an S365-dependent
225 viral control in brain cells, we infected primary neurons and astrocytes *in vitro* with
226 HSV-1. However, we observed similar viral yields and autophagy-related processes
227 (colocalization of virus-LC3 and LC3 conversion) (Supp. Fig.S5a-e) in both cell
228 populations among all genotypes, confirming prior reports that STING does not function
229 cell autonomously in these cell types [42]. To address which cells require S365 for type I
230 IFN induction *in vivo*, we sorted brain cells (neurons, astrocytes and microglia) 3 days
231 post infection from brains of HSV-1-infected mice (ocular route). We found elevated *Ifnb*
232 expression in all cell populations only in WT mice (Fig. 4g-i), confirming that IFN- β
233 induction *in vivo* requires STING S365. Together, our data suggest that STING-mediated
234 control of HSV-1 infection *in vivo* does not require STING S365-induced type I IFN
235 production.



236

237

238 **Figure 4. S365A mice are resistant to ocular HSV-1 infection.** Mice were infected via

239 the ocular route with 1×10^5 PFU of HSV-1 (strain 17). **a**, Percentage of initial weight

240 following infection. **b**, Survival of infected mice. **c**, Viral titers in the brain, **d**, brain stem

241 and **e**, spinal cord from 6 days p.i. **f**, Relative expression of *Ifnb* in the brain stem at 3

242 days p.i. **g**, Brains from infected mice were collected 3 days p.i. and neurons, **h**,

243 astrocytes and **i**, microglia cells were sorted, and *Ifnb* expression was analyzed.

244 Representative of more than five independent experiments. Error bars are SEM.

245 Analyzed with one-way ANOVA and Tukey post-test. *, $p \leq 0.05$; **, $p \leq 0.005$; ***, p

246 ≤ 0.0001 . ns, not significant.

247

STING S365A and *Irf3*^{-/-} mice phenocopy resistance to HSV-1.

248


Because TBK1 has been implicated in autophagy induction [4, 52, 53] whereas

249

IRF3 acts as a transcriptional factor to induce type I IFNs downstream of STING, we

250 investigated the role of these proteins in the context of an *in vivo* infection with HSV-1.
251 *Tbkl*^{-/-} mice die as embryos, but this lethality is reversed on a *Tnfr1*^{-/-} background. We
252 therefore analyzed *Tnfr1*^{-/-} mice compared to *Tbkl*^{-/-}*Tnfr1*^{-/-} double deficient mice.
253 *Tbkl*^{-/-}*Tnfr1*^{-/-} mice lost weight and succumbed to HSV-1 infection at the same rate as
254 *Gt* and Δ CTT mice, whereas *Tnfr1*^{-/-} mice were as resistant to HSV-1 as WT mice (Fig.
255 5a and b). By contrast, *Irf3*^{-/-} mice presented an intermediate phenotype similar to that of
256 S365A mice. Viral loads in brain stems and total brain correlated with the disease
257 severity (Fig. 5c and Supp. Fig. S6a) and *Ifnb* expression in the brain stems was increased
258 only in WT mice (Fig. 5d). *Ifnb* expression was also reproducibly decreased in *Tnfr1*^{-/-}
259 mice *in vivo* (but not *in vitro* Supp. Fig. S6b) for reasons that are currently unclear.
260 Nevertheless, these results suggest that S365A is critical for STING-induced IRF3
261 activation and *Ifnb* expression, but neither S365 nor IRF3 are essential for restriction of
262 HSV-1 replication *in vivo*, whereas the STING CTT and TBK1 are essential.

263



264
 265 **Figure 5. STING S365A and *Irf3*^{-/-} mice phenocopy resistance to HSV-1.** Mice were
 266 ocular infected with 1x10⁵ PFU of HSV-1 (strain 17). **a**, Percentage of initial weight
 267 following infection. **b**, Survival of infected mice. **c**, Viral titers in the brain stem. **d**,
 268 Relative *Ifnb* expression from brain stems. Representative results of at least three
 269 independent experiments. Error bars are SEM. Analyzed with one-way ANOVA and
 270 Tukey post-test. *, p ≤ 0.05; **, p ≤ 0.005; ***, p ≤ 0.0001. ns, not significant.

271

272

Discussion

273

274

275

276

277

278

279

280

281

The cGAS–STING pathway is a critical innate immune sensing pathway for the detection and elimination of DNA viruses, including HSV-1. STING activation leads to a variety of downstream antiviral responses, including IRF3-dependent induction of type I IFNs, as well as NF-κB activation and induction of autophagy responses. However, the relative contributions of these various STING-induced responses to host defense *in vivo* remains unclear. By generation and analysis of STING S365A and ΔCTT mice, we were able to investigate the role of distinct STING-dependent signaling events during HSV-1 infection. Using both a systemic and an eye infection HSV-1 model, we found that S365A mice are relatively resistant to infection, as compared to STING null *Gt* mice or to

282 STING Δ CTT mice. STING S365A mice failed to induce type I IFNs in response to
283 HSV-1. We therefore propose that an interferon-independent function of STING is
284 critical during HSV-1 infection *in vivo*. IRF3 is activated downstream of STING via
285 recruitment to phospho-S365, and IRF3 is required for type I IFN induction by STING.
286 Interestingly, we also found that *Irf3*^{-/-} mice are relatively resistant to HSV-1 infection.
287 By contrast, *Gt*, STING Δ CTT and *Tbk1*^{-/-}*Tnfr1*^{-/-} mice are fully susceptible to HSV-1.
288 TBK1 recruitment and activation by STING requires the CTT but is independent of S365.
289 Thus, we propose that the interferon- and IRF3-independent function of STING that
290 protects against HSV-1 is initiated upon TBK1 recruitment by the STING CTT.

291 Although the exact mechanism that mediates protection to HSV-1 downstream of
292 the STING CTT and TBK1 remains to be elucidated, we propose that a strong candidate
293 is autophagy or an autophagy-like process. Indeed, we found that STING S365A is still
294 able to induce the autophagy-like formation of LC3 puncta (Fig. 1d-f), a process
295 previously shown also to require TBK1 [28, 52]. Autophagy has previously been shown
296 to be critical for control of HSV-1 [45]. However, it remains possible that an unidentified
297 CTT–TBK1-induced response (other than, or in addition to, autophagy) is critical for
298 STING-dependent control of HSV-1. Future studies are required to better elucidate the
299 mechanism of STING-induced autophagy or other STING-induced responses, as there is
300 no way at present to selectively eliminate STING-induced autophagy (or the putative
301 autophagy-independent CTT–TBK1-dependent process). Nevertheless, our results clearly
302 demonstrate the existence of effective S365/IRF3/interferon-independent antiviral
303 functions for STING.

304 Type I IFNs are essential for control of HSV-1 [41, 43, 46-48], a result we have
305 confirmed (Supp. Fig. S6c-d). Thus, our results suggest only that STING-induced IFN, as
306 opposed to all sources of type I IFN, is dispensable for resistance to HSV-1. Although we
307 observe that most type I IFN induction during HSV-1 requires STING (Fig. 4f-i), other
308 pathways for type I IFN induction (particularly the TLR3 pathway) [54-56] have been
309 reported and appear to provide a low but essential type I IFN response.

310 Autophagy has been implicated in direct antiviral defense in many neurotropic
311 viruses infections both *in vivo* and *in vitro* [45, 57-59]. In fact, HSV-1 has evolved
312 different mechanisms to evade autophagy [58, 60, 61], but how STING activation
313 initiates autophagy and whether STING-induced autophagy contributes to control of
314 HSV-1 is not clear. In addition, the involvement of TBK1 during autophagy has been a
315 matter of discussion. Some studies show that cells lacking TBK1 can still maintain
316 autophagy-like events (LC3 conversion, puncta formation and autophagosomes
317 formation) [16, 62] while other evidence suggests a critical role for TBK1 in
318 phosphorylation of selective autophagy receptors and STING autophagosomal
319 degradation [63, 64]. Importantly, our data in primary cells suggest that TBK1 is needed
320 for STING-mediated autophagy

321 One interesting feature of our results is that the STING S365A-independent
322 protection we observe is delayed, especially in the eye infection model, and is coincident
323 with the onset of adaptive T cell responses. Autophagy has been linked to induction of T
324 cell responses [65-67]. Thus, one attractive possibility is that autophagy is required for
325 antigen processing and presentation to elicit protective adaptive immune responses. Our

326 newly generated STING mutant mice represent valuable tools to dissect this and other
327 putative IFN-independent functions of STING *in vivo*.

328

329 References

- 330 1. Janeway, C.A., Jr., *Approaching the asymptote? Evolution and revolution in*
331 *immunology*. Cold Spring Harb Symp Quant Biol, 1989. **54 Pt 1**: p. 1-13.
- 332 2. Sorensen, L.N., et al., *TLR2 and TLR9 synergistically control herpes simplex*
333 *virus infection in the brain*. J Immunol, 2008. **181**(12): p. 8604-12.
- 334 3. Watson, R.O., et al., *The Cytosolic Sensor cGAS Detects Mycobacterium*
335 *tuberculosis DNA to Induce Type I Interferons and Activate Autophagy*. Cell Host
336 Microbe, 2015. **17**(6): p. 811-819.
- 337 4. Watson, R.O., P.S. Manzanillo, and J.S. Cox, *Extracellular M. tuberculosis DNA*
338 *targets bacteria for autophagy by activating the host DNA-sensing pathway*. Cell,
339 2012. **150**(4): p. 803-15.
- 340 5. Gao, P., et al., *Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger*
341 *produced by DNA-activated cyclic GMP-AMP synthase*. Cell, 2013. **153**(5): p.
342 1094-107.
- 343 6. Kranzusch, P.J., et al., *Structure of human cGAS reveals a conserved family of*
344 *second-messenger enzymes in innate immunity*. Cell Rep, 2013. **3**(5): p. 1362-8.
- 345 7. Sun, L., et al., *Cyclic GMP-AMP synthase is a cytosolic DNA sensor that*
346 *activates the type I interferon pathway*. Science, 2013. **339**(6121): p. 786-91.
- 347 8. Diner, E.J., et al., *The innate immune DNA sensor cGAS produces a noncanonical*
348 *cyclic dinucleotide that activates human STING*. Cell Rep, 2013. **3**(5): p. 1355-61.
- 349 9. Zhang, X., et al., *Cyclic GMP-AMP containing mixed phosphodiester linkages is*
350 *an endogenous high-affinity ligand for STING*. Mol Cell, 2013. **51**(2): p. 226-35.
- 351 10. Ablasser, A., et al., *cGAS produces a 2'-5'-linked cyclic dinucleotide second*
352 *messenger that activates STING*. Nature, 2013. **498**(7454): p. 380-4.
- 353 11. Cohen, D., et al., *Cyclic GMP-AMP signalling protects bacteria against viral*
354 *infection*. Nature, 2019.
- 355 12. Margolis, S.R., S.C. Wilson, and R.E. Vance, *Evolutionary Origins of cGAS-*
356 *STING Signaling*. Trends Immunol, 2017. **38**(10): p. 733-743.
- 357 13. Liu, Y., et al., *Inflammation-Induced, STING-Dependent Autophagy Restricts*
358 *Zika Virus Infection in the Drosophila Brain*. Cell Host Microbe, 2018. **24**(1): p.
359 57-68 e3.
- 360 14. Goto, A., et al., *The Kinase IKKbeta Regulates a STING- and NF-kappaB-*
361 *Dependent Antiviral Response Pathway in Drosophila*. Immunity, 2018. **49**(2): p.
362 225-234 e4.
- 363 15. Martin, M., et al., *Analysis of Drosophila STING Reveals an Evolutionarily*
364 *Conserved Antimicrobial Function*. Cell Rep, 2018. **23**(12): p. 3537-3550 e6.
- 365 16. Gui, X., et al., *Autophagy induction via STING trafficking is a primordial function*
366 *of the cGAS pathway*. Nature, 2019. **567**(7747): p. 262-266.
- 367 17. Sauer, J.D., et al., *The N-ethyl-N-nitrosourea-induced Goldenticket mouse mutant*
368 *reveals an essential function of Sting in the in vivo interferon response to Listeria*
369 *monocytogenes and cyclic dinucleotides*. Infect Immun, 2011. **79**(2): p. 688-94.

- 370 18. Liu, S., et al., *Phosphorylation of innate immune adaptor proteins MAVS, STING,*
371 *and TRIF induces IRF3 activation.* Science, 2015. **347**(6227): p. aaa2630.
- 372 19. Konno, H., K. Konno, and G.N. Barber, *Cyclic dinucleotides trigger ULK1*
373 *(ATG1) phosphorylation of STING to prevent sustained innate immune signaling.*
374 Cell, 2013. **155**(3): p. 688-98.
- 375 20. Tanaka, Y. and Z.J. Chen, *STING specifies IRF3 phosphorylation by TBK1 in the*
376 *cytosolic DNA signaling pathway.* Sci Signal, 2012. **5**(214): p. ra20.
- 377 21. Zhao, B., et al., *A conserved PLPLRT/SD motif of STING mediates the*
378 *recruitment and activation of TBK1.* Nature, 2019. **569**(7758): p. 718-722.
- 379 22. Zhang, C., et al., *Structural basis of STING binding with and phosphorylation by*
380 *TBK1.* Nature, 2019. **567**(7748): p. 394-398.
- 381 23. Motwani, M., S. Pesiridis, and K.A. Fitzgerald, *DNA sensing by the cGAS-STING*
382 *pathway in health and disease.* Nat Rev Genet, 2019. **20**(11): p. 657-674.
- 383 24. Tan, X., et al., *Detection of Microbial Infections Through Innate Immune Sensing*
384 *of Nucleic Acids.* Annu Rev Microbiol, 2018. **72**: p. 447-478.
- 385 25. Conlon, J., et al., *Mouse, but not human STING, binds and signals in response to*
386 *the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.* J Immunol,
387 2013. **190**(10): p. 5216-25.
- 388 26. Guo, F., et al., *STING agonists induce an innate antiviral immune response*
389 *against hepatitis B virus.* Antimicrob Agents Chemother, 2015. **59**(2): p. 1273-81.
- 390 27. Louis, C., C. Burns, and I. Wicks, *TANK-Binding Kinase 1-Dependent Responses*
391 *in Health and Autoimmunity.* Front Immunol, 2018. **9**: p. 434.
- 392 28. Saitoh, T., et al., *Atg9a controls dsDNA-driven dynamic translocation of STING*
393 *and the innate immune response.* Proc Natl Acad Sci U S A, 2009. **106**(49): p.
394 20842-6.
- 395 29. Rasmussen, S.B., et al., *Activation of autophagy by alpha-herpesviruses in*
396 *myeloid cells is mediated by cytoplasmic viral DNA through a mechanism*
397 *dependent on stimulator of IFN genes.* J Immunol, 2011. **187**(10): p. 5268-76.
- 398 30. Manzanillo, P.S., et al., *Mycobacterium tuberculosis activates the DNA-dependent*
399 *cytosolic surveillance pathway within macrophages.* Cell Host Microbe, 2012.
400 **11**(5): p. 469-80.
- 401 31. Collins, A.C., et al., *Cyclic GMP-AMP Synthase Is an Innate Immune DNA*
402 *Sensor for Mycobacterium tuberculosis.* Cell Host Microbe, 2015. **17**(6): p. 820-
403 8.
- 404 32. Wassermann, R., et al., *Mycobacterium tuberculosis Differentially Activates*
405 *cGAS- and Inflammasome-Dependent Intracellular Immune Responses through*
406 *ESX-1.* Cell Host Microbe, 2015. **17**(6): p. 799-810.
- 407 33. Antonelli, L.R., et al., *Intranasal Poly-IC treatment exacerbates tuberculosis in*
408 *mice through the pulmonary recruitment of a pathogen-permissive*
409 *monocyte/macrophage population.* J Clin Invest, 2010. **120**(5): p. 1674-82.
- 410 34. Dorhoi, A., et al., *Type I IFN signaling triggers immunopathology in tuberculosis-*
411 *susceptible mice by modulating lung phagocyte dynamics.* Eur J Immunol, 2014.
412 **44**(8): p. 2380-93.
- 413 35. Manca, C., et al., *Virulence of a Mycobacterium tuberculosis clinical isolate in*
414 *mice is determined by failure to induce Th1 type immunity and is associated with*
415 *induction of IFN-alpha /beta.* Proc Natl Acad Sci U S A, 2001. **98**(10): p. 5752-7.

- 416 36. Ji, D.X., et al., *Type I interferon-driven susceptibility to Mycobacterium*
417 *tuberculosis is mediated by IL-1Ra*. Nat Microbiol, 2019.
- 418 37. Siqueira, M.D.S., R.M. Ribeiro, and L.H. Travassos, *Autophagy and Its*
419 *Interaction With Intracellular Bacterial Pathogens*. Front Immunol, 2018. **9**: p.
420 935.
- 421 38. Marinho, F.V., et al., *The cGAS/STING Pathway Is Important for Dendritic Cell*
422 *Activation but Is Not Essential to Induce Protective Immunity against*
423 *Mycobacterium tuberculosis Infection*. J Innate Immun, 2018. **10**(3): p. 239-252.
- 424 39. Nakajima, A., et al., *Cell type-dependent proapoptotic role of Bcl2L12 revealed*
425 *by a mutation concomitant with the disruption of the juxtaposed Irf3 gene*. Proc
426 Natl Acad Sci U S A, 2009. **106**(30): p. 12448-52.
- 427 40. Ishikawa, H., Z. Ma, and G.N. Barber, *STING regulates intracellular DNA-*
428 *mediated, type I interferon-dependent innate immunity*. Nature, 2009. **461**(7265):
429 p. 788-92.
- 430 41. Christensen, M.H., et al., *HSV-1 ICP27 targets the TBK1-activated STING*
431 *signalsome to inhibit virus-induced type I IFN expression*. EMBO J, 2016. **35**(13):
432 p. 1385-99.
- 433 42. Reinert, L.S., et al., *Sensing of HSV-1 by the cGAS-STING pathway in microglia*
434 *orchestrates antiviral defence in the CNS*. Nat Commun, 2016. **7**: p. 13348.
- 435 43. Su, C., G. Zhan, and C. Zheng, *Evasion of host antiviral innate immunity by HSV-*
436 *I, an update*. Virol J, 2016. **13**: p. 38.
- 437 44. Shen, G., et al., *Herpes simplex virus 1 counteracts viperin via its virion host*
438 *shutoff protein UL41*. J Virol, 2014. **88**(20): p. 12163-6.
- 439 45. Yordy, B., et al., *A neuron-specific role for autophagy in antiviral defense against*
440 *herpes simplex virus*. Cell Host Microbe, 2012. **12**(3): p. 334-45.
- 441 46. Leib, D.A., et al., *Interferons regulate the phenotype of wild-type and mutant*
442 *herpes simplex viruses in vivo*. J Exp Med, 1999. **189**(4): p. 663-72.
- 443 47. Wilcox, D.R., et al., *The Type I Interferon Response Determines Differences in*
444 *Choroid Plexus Susceptibility between Newborns and Adults in Herpes Simplex*
445 *Virus Encephalitis*. MBio, 2016. **7**(2): p. e00437-16.
- 446 48. Ceron, S., et al., *The STING agonist 5,6-dimethylxanthenone-4-acetic acid*
447 *(DMXAA) stimulates an antiviral state and protects mice against herpes simplex*
448 *virus-induced neurological disease*. Virology, 2019. **529**: p. 23-28.
- 449 49. Nicoll, M.P., J.T. Proenca, and S. Efstathiou, *The molecular basis of herpes*
450 *simplex virus latency*. FEMS Microbiol Rev, 2012. **36**(3): p. 684-705.
- 451 50. Steiner, I. and F. Benninger, *Update on herpes virus infections of the nervous*
452 *system*. Curr Neurol Neurosci Rep, 2013. **13**(12): p. 414.
- 453 51. Parker, Z.M., A.A. Murphy, and D.A. Leib, *Role of the DNA Sensor STING in*
454 *Protection from Lethal Infection following Corneal and Intracerebral Challenge*
455 *with Herpes Simplex Virus 1*. J Virol, 2015. **89**(21): p. 11080-91.
- 456 52. Pilli, M., et al., *TBK-1 promotes autophagy-mediated antimicrobial defense by*
457 *controlling autophagosome maturation*. Immunity, 2012. **37**(2): p. 223-34.
- 458 53. Weidberg, H. and Z. Elazar, *TBK1 mediates crosstalk between the innate immune*
459 *response and autophagy*. Sci Signal, 2011. **4**(187): p. pe39.
- 460 54. Zhang, S.Y., et al., *TLR3 deficiency in patients with herpes simplex encephalitis*.
461 Science, 2007. **317**(5844): p. 1522-7.

- 462 55. Reinert, L.S., et al., *TLR3 deficiency renders astrocytes permissive to herpes*
463 *simplex virus infection and facilitates establishment of CNS infection in mice.* J
464 Clin Invest, 2012. **122**(4): p. 1368-76.
- 465 56. Zimmer, B., et al., *Human iPSC-derived trigeminal neurons lack constitutive*
466 *TLR3-dependent immunity that protects cortical neurons from HSV-1 infection.*
467 Proc Natl Acad Sci U S A, 2018. **115**(37): p. E8775-E8782.
- 468 57. Orvedahl, A., et al., *Autophagy protects against Sindbis virus infection of the*
469 *central nervous system.* Cell Host Microbe, 2010. **7**(2): p. 115-27.
- 470 58. Orvedahl, A., et al., *HSV-1 ICP34.5 confers neurovirulence by targeting the*
471 *Beclin 1 autophagy protein.* Cell Host Microbe, 2007. **1**(1): p. 23-35.
- 472 59. Chaumorcel, M., et al., *Human cytomegalovirus controls a new autophagy-*
473 *dependent cellular antiviral defense mechanism.* Autophagy, 2008. **4**(1): p. 46-53.
- 474 60. Gobeil, P.A. and D.A. Leib, *Herpes simplex virus gamma34.5 interferes with*
475 *autophagosome maturation and antigen presentation in dendritic cells.* MBio,
476 2012. **3**(5): p. e00267-12.
- 477 61. Alexander, D.E., et al., *Analysis of the role of autophagy in replication of herpes*
478 *simplex virus in cell culture.* J Virol, 2007. **81**(22): p. 12128-34.
- 479 62. Liu, D., et al., *STING directly activates autophagy to tune the innate immune*
480 *response.* Cell Death Differ, 2018.
- 481 63. Richter, B., et al., *Phosphorylation of OPTN by TBK1 enhances its binding to Ub*
482 *chains and promotes selective autophagy of damaged mitochondria.* Proc Natl
483 Acad Sci U S A, 2016. **113**(15): p. 4039-44.
- 484 64. Prabakaran, T., et al., *Attenuation of cGAS-STING signaling is mediated by a*
485 *p62/SQSTM1-dependent autophagy pathway activated by TBK1.* EMBO J, 2018.
486 **37**(8).
- 487 65. English, L., et al., *Autophagy enhances the presentation of endogenous viral*
488 *antigens on MHC class I molecules during HSV-1 infection.* Nat Immunol, 2009.
489 **10**(5): p. 480-7.
- 490 66. Budida, R., et al., *Herpes simplex virus 1 interferes with autophagy of murine*
491 *dendritic cells and impairs their ability to stimulate CD8(+) T lymphocytes.* Eur J
492 Immunol, 2017. **47**(10): p. 1819-1834.
- 493 67. Dengjel, J., et al., *Autophagy promotes MHC class II presentation of peptides*
494 *from intracellular source proteins.* Proc Natl Acad Sci U S A, 2005. **102**(22): p.
495 7922-7.
- 496 68. Wang, H., et al., *One-step generation of mice carrying mutations in multiple*
497 *genes by CRISPR/Cas-mediated genome engineering.* Cell, 2013. **153**(4): p. 910-
498 8.
- 499 69. Ishii, K.J., et al., *TANK-binding kinase-1 delineates innate and adaptive immune*
500 *responses to DNA vaccines.* Nature, 2008. **451**(7179): p. 725-9.
- 501 70. Mayer-Barber, K.D., et al., *Caspase-1 independent IL-1beta production is critical*
502 *for host resistance to mycobacterium tuberculosis and does not require TLR*
503 *signaling in vivo.* J Immunol, 2010. **184**(7): p. 3326-30.
- 504 71. Posel, C., et al., *Isolation and Flow Cytometric Analysis of Immune Cells from the*
505 *Ischemic Mouse Brain.* J Vis Exp, 2016(108): p. 53658.
- 506

507 **Acknowledgements:** We thank members of the Vance, Barton, Stanley and Cox labs for
508 discussions, L. Flores, P. Dietzen and R. Chavez for technical assistance, H. Nolla and A.
509 Valeros and the Cancer Research Laboratory for flow cytometry. We thank Dr. Mary
510 West and Dr. Pingping He of the High-Throughput Screening Facility (HTSF) at UC
511 Berkeley. This work was performed in part in the HTSF, which provided the Perkin
512 Elmer Opera Phenix, funded by NIH Instrument Grant S10OD021828 with the assistance
513 of Christopher Noel. We thank Chris Bowen and Daniel Renner in the Szpara lab for
514 assistance with viral genome sequencing and analysis. R.E.V. was supported by
515 Investigator in the Pathogenesis of Infectious Diseases awards from the Burroughs
516 Wellcome Fund. R.E.V. is an HHMI Investigator and is supported by NIH grants
517 AI075039 and AI066302. The authors declare no competing interests.

518

519 **Materials and Methods**

520 **Viruses and reagents.** Dulbecco's Modified Eagle Medium (DMEM) was obtained from
521 Gibco and supplemented with 100 U/ml penicillin, 100 mM streptomycin and LPS-free
522 FCS (BioWhittaker). DAPI, TRIzol, Poly I:C (all from Invitrogen) Lipofectamine 2000
523 (Invitrogen) were used in the experiments described below. HSV-1 (strains KOS and
524 strain 17) was grown in Vero cells. The Vero cells used were from the lab stock. The
525 titers of the stocks used were $8-14 \times 10^9$ PFU/ml. Titters were determined by TCID50
526 assay on Vero cells. Both strains were used for infection of mice, while only KOS strain
527 was used for *in vitro* stimulation.

528 **Mice.** All mice used were specific pathogen free, maintained under a 12 h light-dark
529 cycle (7 am to 7 pm), and given a standard chow diet (Harlan irradiated laboratory animal
530 diet) ad libitum. Wild type C57BL/6J mice were originally obtained from the Jackson
531 Laboratories (JAX). CRISPR/Cas9 targeting was performed by both pronucleus and
532 cytoplasm injection of Cas9 mRNA, sgRNA, and repair template oligos into fertilized
533 zygotes from C57BL/6J female mice (JAX, stock no. 000664), essentially as described
534 previously[68]. STING S365A mice were generated by targeting exon 8 from

535 STING introducing an AGT (serine) to GCC (alanine) substitution at codon 365. The
536 sgRNA sequence was 5' – GCTGATCCATAACCACTGATG – 3' and the repair template
537 oligo was
538 C*A*G*ACAAGGCTGTCCCATGCCTCAGATGAGGTCAGTGCGGAGTGGGAGA
539 GGCTGATCCATAACCGGCGATGAGGAGTCTTGGCTCTTGGGACAGTACGGAGG
540 GAGGAGGTGCCACTGA*G*G*T (underlined is the PAM location). For STING
541 Δ CTT mice, valine 340 was replaced by a premature stop codon. The sgRNA sequence
542 was 3' – GGAGGAAAAGAAGGACTGCT - 5' and the repair template oligo was
543 C*C*C*ACAGACGGAAACAGTTTCTCACTGTCTCAGGAGGTGCTCCGGCACAT
544 TCGTCAGGAAGAAAAGGAGGAGTGAACCATGAATGCCCCCATGACCTCAGTG
545 GCACCTCCTCCCTCC*G*T*A (underlined is the PAM location). The asterisks
546 indicate phosphorothioate linkages in the first and last three nucleotides. *Irf3*^{-/-} mice were
547 generated by targeting exon 6 from IRF3. The sgRNA sequence was
548 5' – GAGGTGACCGCCTTCTACCG – 3'. Founder mice were genotyped as described
549 below, and founders carrying mutations were bred one generation to C57BL/6J mice to
550 separate modified haplotypes. Homozygous lines were generated by interbreeding
551 heterozygotes carrying matched haplotypes. *Tbk1*^{-/-}*Tnfr1*^{-/-} and *Tnfr1*^{-/-} mice were
552 described elsewhere[69].

553 **Preparation of gRNA transcript.** DNA oligos (IDT, Coralville, NY) were heated to
554 95°C followed by cooling down to room temperature. The self-annealing oligo duplex
555 was cloned into linearized T7 gRNA vector (System Biosciences, Mountain View, CA
556 USA). The cloned sgRNA was sequence verified by DNA sequencing. Then sgRNA
557 template for in vitro transcription (IVT) was prepared by PCR amplification of Phusion
558 high fidelity DNA polymerase (NEB Biolabs, Ipswich, MA), the PCR mixture was
559 cleaned up by PCR cleanup reaction (Qiagen, Hilden, Germany). The sgRNA transcripts
560 were generated by IVT synthesis kit (System Biosciences, Palo Alto, CA). Quality of
561 sgRNA transcripts was analyzed by NanoDrop (Thermo Fisher Scientific, Waltham, MA)
562 and Bioanalyzer instrument (Agilent Technologies, Inc., Santa Clara, CA).

563 **Genotyping of STING S365A, Δ CTT and *Irf3* alleles.** Exon 8 of STING and Exon 6 of
564 *Irf3* were amplified by PCR using the following primers (all 5' to 3'): S365A fwd: CCA
565 ACC ATT GAA GGA AGG CTC AGT C, S365A rev: CTC ACT GTC TCA GGA GGT

566 GCT CC; Δ CTT fwd: CTA GAG CCC AGA CAA GGC TGT CC, Δ CTT rev: CCC ACA
567 GAC GGA AAC AGT TTC TCA C; *Irf3* fwd: AAC GTG AGT GCC AGC TGT GG,
568 *Irf3* rev: CTT CAC AAG CTT GTC CGT CAG AAA CC. Primers were used at 200nM
569 in a reaction with 2.5mM MgCl₂ and 75 μ M dNTPs and 1 Unit Taq polymerase (Thermo
570 Fisher Scientific) per reaction. Cleaned PCR products were diluted 1:16 and sequenced
571 using Sanger sequencing (Berkeley DNA Sequencing facility).

572 **Cell culture.** Macrophages were derived from the bone marrow of C57BL/6J or STING
573 mutant (*Gt*, S365A or Δ CTT) mice. Macrophages were derived by 7 days of culture in
574 RPMI 1640 medium supplemented with 10% serum, 100 mM streptomycin, 100 U/ml
575 penicillin, 2 mM L-glutamine and 10% supernatant from 3T3-M-CSF cells, with feeding
576 on day 5. Mouse primary microglia cells and astrocytes were isolated and cultured from
577 the cerebrum of P0 pups. Neonatal cerebra were trypsinized for 20 min and filtered
578 through a 70 μ m pore size filter. Cells of 3 cerebrum were seeded on one poly-d-lysine-
579 coated 75 cm² culture flask and incubated with DMEM containing 10% FCS. The
580 medium was replaced on day 2 after plating. Henceforth, either microglia or astrocytes
581 were isolated. Astrocytes were isolated using the following method: after 7 days of
582 culture, cells were shaken for 30 minutes, supernatant was aspirated, and the remaining
583 adherent cells were predominantly astrocytes. Purity of each population was determined
584 by FACS. Primary dissociated hippocampal cultures were prepared from postnatal day 0-
585 1 (P0-1). Mice were euthanized using standard protocols. Briefly, bilateral hippocampi
586 from 2-3 pups were dissected on ice and pooled together. The tissue was dissociated
587 using 34.4 μ g/ml papain in dissociation media (HBSS Ca²⁺, Mg²⁺ free, 1mM sodium
588 pyruvate, 0.1% D-glucose, 10mM HEPES buffer) and incubated for 3 min at 37° C. The
589 papain was neutralized by incubation in trypsin inhibitor (1mg/ml in dissociation media)
590 at 37°C for 4 min. After incubation, the dissociation media was carefully removed and
591 the tissue was gently triturated, manually, in plating media (MEM, 10% FBS, 0.45% D-
592 Glucose, 1mM sodium pyruvate, 1mM L-glutamine). Cell density was counted using a
593 TC10 Automated cell counter (Biorad). For western blot experiments, 2.2-2.5 \times 10⁵ cells
594 were plated onto 24- well plates pre-coated with Poly-D-Lysine (PDL) (Corning) in
595 500 μ l of plating media. After 3 hours, plating media was removed and 800 μ l maintenance
596 media (Neurobasal media (GIBCO) with 2mM glutamine, pen/strep, and B-27

597 supplement (GIBCO)) was added per well. After 4 days in vitro 1uM cytosine
598 arabinoside (Sigma) was added to prevent glial proliferation. Neurons were maintained in
599 maintenance media for 14 days with partial media changes every 4 days. For
600 immunofluorescence, 2×10^3 cells were plated in pre-coated 96 well plates (CellCarrier-
601 96 Ultra Microplates, black, PerkinElmer) following the same procedure.

602 **Murine *M. tuberculosis* infections.** *M. tuberculosis* strain Erdman (gift of S.A. Stanley)
603 was used for all infections. Frozen stocks of this wild-type strain were made from a single
604 culture and used for all experiments. Cultures for infection were grown in Middlebrook
605 7H9 liquid medium supplemented with 10% albumin-dextrose-saline, 0.4% glycerol and
606 0.05% Tween-80 for five days at 37°C. Mice were aerosol infected using an inhalation
607 exposure system (Glas-Col, Terre Haute, IN). A total of 9 ml of culture was loaded into
608 the nebulizer calibrated to deliver ~400 bacteria per mouse as measured by colony
609 forming units (CFUs) in the lungs 1 day following infection (data not shown). Mice were
610 sacrificed at various days post-infection as indicated in the figure legends to measure
611 CFUs and/or cytokines. All lung lobes were homogenized in PBS plus 0.05% Tween- 80
612 or processed for cytokines (see below), and serial dilutions were plated on 7H11 plates
613 supplemented with 10% oleic acid, albumin, dextrose, catalase (OADC) and 0.5%
614 glycerol. CFUs were counted 21-25 days after plating.

615 **Cytokine measurements.** Cell-free lung homogenates from *M. tuberculosis* infected
616 mice were generated as previously described[70]. Briefly, lungs were dissociated through
617 100 µm Falcon cell strainers in sterile PBS with 1% FBS and Pierce Protease Inhibitor
618 EDTA-free (Thermo Fisher). An aliquot was removed for measuring CFU by plating as
619 described above. Cells and debris were then removed by first a low-speed centrifugation
620 (approximately 300×g) then a high- speed centrifugation (approximately 2000×g) and the
621 resulting cell-free homogenate was filtered twice with 0.2 µm filters to remove all *M.*
622 *tuberculosis* for work outside of BSL3. All homogenates were aliquoted, flash-frozen in
623 liquid nitrogen and stored at -80°C. Each aliquot was thawed a maximum of twice to
624 avoid potential artifacts due to repeated freeze-thaw cycles. All cytokines were measured
625 using Cytometric Bead Assay (BD Biosciences) according to manufacturer protocols.
626 TNF-α from DMXAA and LPS stimulated mice was also measured by CBA. Results

627 were collected using BD LSRFortessa (BD Biosciences) and analyzed using GraphPad
628 Prism v6.0c. TNF- α from primary macrophages supernatant was measured by ELISA.

629 **Murine HSV-1 infection models**

630 **Intravenous infection.** Age and sex matched (7–10-week old) mice were warmed under
631 a lamp for venous dilation and inoculated with 1×10^6 PFU HSV-1 (KOS strain) in 200 μ l
632 of PBS or mock infected with PBS only.

633 **Ocular infection.** Age and sex matched (7–10-week old) mice, were anaesthetized with
634 intraperitoneal (i.p.) injection of ketamine (100 mg/kg body weight) and xylazine
635 (10 mg/kg body weight). Corneas were scarified using a 25G needle and mice were either
636 inoculated with 1×10^5 PFU HSV-1 (strain 17) in 5 μ l, or mock infected with 5 μ l of
637 PBS. Eyewash was collected by gently proptosing each eye and wiping a sterile cotton
638 swab around the eye in a circular motion. The swabs were placed in 0.5 ml of DMEM
639 medium and stored at -80°C until the titer was determined. Whole brains, brain stems,
640 spinal cords and livers were frozen immediately at -80°C . Tissues were homogenized
641 with tissue homogenizer (Polytron PT 2500 E) for 2 min at frequency 10. Tissues were
642 used for RNA isolation with TRIzol or used for virus titration.

643 **Scoring and tissue harvest.** Mice were scored for disease, weighed at the indicated
644 times post infection and euthanized at the specified times post infection for tissue
645 harvesting or once they met end point criteria. The scoring was performed as blinded
646 study, largely following previous descriptions by others[51] with the following minor
647 modifications: symptoms related to neurological disease named body condition score
648 (BCS) (0: normal, healthy 1: hunched, 2: uncoordinated, lethargic, mild paralysis, 3:
649 unresponsive/no movement, complete paralysis).

650 **Infection and cell stimulations (transfections).** For infections, bone marrow derived
651 macrophages from C57BL/6J mice were plated at $1-2 \times 10^6$ cells/well. The next day they
652 were stimulated with cyclic dinucleotides c-di-GMP, 2'3'cGAMP, Sendai virus (SeV)
653 and poly I:C. Cells were transfected using Lipofectamine 2000 (LF2000; Invitrogen)
654 according to the manufacturer's protocol. All cyclic dinucleotides nucleic acid stimulants
655 were mixed with LF2000 at a ratio of 1 μ l LF2000/1 μ g nucleic acid, incubated at room
656 temperature for 20–30 min, and added to cells at a final concentration of 4 μ g/ml (6-well
657 plates). For Sendai Virus, cells were infected at 150 hemagglutination units (HAU)/ml.

658 For poly I:C, 2 mg/ml of the stock solution was heated at 50°C for 10 min and cooled to
659 room temperature before mixing with LF2000. Transfection experiments were done for 6
660 h, unless otherwise stated in the figures.

661 **Immunoblotting.** BMMs were seeded at a density of 1×10^6 cells per well in 6 well tissue
662 culture plates and transfected the next day using Lipofectamine 2000 (Invitrogen)
663 according to the manufacturer's instruction. Cells were lysed at indicated time post
664 transfection with radioimmunoprecipitation assay (RIPA) buffer supplemented with 2
665 mM NaVO₃, 50 mM b-Glycerophosphate, 50 mM NaF, 2 mM PMSF, and Complete
666 Mini EDTA-free Protease Inhibitor (Roche). Proteins separated with denaturing PAGE
667 and transferred to Immobilon-FL PVDF membranes (Millipore). Membranes were
668 blocked with Li-Cor Odyssey blocking buffer. Primary antibodies were added and
669 incubated overnight. Primary antibodies used were: anti-TBK1 (D1B4) (#3504), anti-
670 phospho-TBK1/NAK (Ser172) (D52C2) (#5483), anti-STING (D2P2F) (#13647), anti-
671 phospho-STING (Ser366) (D7C3S) (#19781), anti-phospho-IRF3 (Ser396) (4D4G)
672 (#4947), all purchased from Cell Signaling Technologies. Anti-IRF3 (EP2419Y)
673 (#ab76409) was from Abcam. Secondary anti-rabbit IgG was conjugated to Alexa Fluor-
674 680 (Invitrogen). Immunoblots were imaged using a Li-Cor fluorimeter.

675 **Quantitative PCR.** Stimulated cells were overlaid with TRIzol (Invitrogen) and stored.
676 RNA was isolated according to the manufacturer's protocol and was treated with RQ1
677 RNase-free DNase (Promega). 0.5 µg RNA was reverse transcribed with Superscript III
678 (Invitrogen). SYBRGreen dye (ThermoFisher Scientific) was used for quantitative PCR
679 assays and analyzed with a real-time PCR system (StepOnePlus; Applied Biosystems).
680 All gene expression values were normalized to *Rps17* (mouse) levels for each sample.

681 The following primer sequences were used: mouse *Ifnb*, (forward) 5'-
682 ATAAGCAGCTCCAGCTCCAA-3' and (reverse) 5'-CTGTCTGCTGGTGGAGTTCA-
683 3'; mouse *Rps17*, (forward) 5'-CGCCATTATCCCCAGCAAG-3' and (reverse) 5'-
684 TGTCGGGATCCACCTCAATG-3'; mouse *Viperin*, (forward) 5'-
685 TTGGGCAAGCTTGTGAGATTC-3' and (reverse) 5'-
686 TGAACCATCTCTCCTGGATAAGG-3'; mouse *TNF*, (forward) 5'-
687 TCTTCTCATTCCTGCTTG TGG-3' and (reverse) 5'-GGTCTGGGCCATAGAACTGA-

688 3'; mouse *IL-6*, (forward) 5'-GCTACCAAACCTGGATATAATCAGGA-3' and (reverse)
689 5'-CCAGGTAGCTATGGTACTCCAGAA-3'.

690 **Immunofluorescence and high-content imaging.** Bone marrow derived macrophages
691 were transfected with 0.2 ug of Cy3-labeled DNA for 6 hours. Cells were washed with
692 PBS, fixed in 4% paraformaldehyde and ice-cold methanol. Cells were washed 3x with
693 PBS and blocked and permeabilized with 2% BSA and 0.3% Triton X100. LC3 puncta
694 staining was performed using mouse monoclonal antibody (Nanotools, catalog #0260-
695 100/LC3-2G6 at 1:400, RT) for 3hours, followed by secondary goat anti-mouse IgG
696 labeled with Alexa Fluor 488 (Life Technologies at 1:4000, RT) for 1 hour. Nuclei were
697 stained with DAPI. For imaging, cells in 96-well plates were imaged using an Opera
698 Phenix (Perkin Elmer) at RT, using a $\times 40$ 1.1 NA water immersion lens (Zeiss). Images
699 were exported to Harmony High-Content Imaging and Analysis Software and automated
700 colocalization measurements were performed with the Perkin Elmer Harmony software
701 package. A pipeline was created to measure colocalization of Cy3-labeled DNA and LC3.
702 Quantification was performed using data collected from 16 fields per well in 96-well
703 format. Data was then analyzed in Prism using one-way ANOVA analysis.

704 **Flow cytometry.** Single suspensions were prepared from each experimental group using
705 a modified protocol as described[71]. To analyze tetramer positive cells, cell suspensions
706 were stained with the following cell surface antibodies: CD3e (clone 145-2C11, BD
707 Horizon), CD8a (clone 53-6.7, Biolegend), CD45 (clone 30-F11, eBioscience), CD44
708 (clone IM7, eBioscience), CD11b (clone M1/70, eBioscience), MHCII I-A/I-E
709 (cloneM5/114.15.2, Biolegend), CD19 (clone eBio1D3, eBioscience), CD45R (B220)
710 (clone RA3-6B2, Invitrogen), Ly6G (Gr-1) (clone 1A8-Ly6g, eBioscience). Samples
711 were acquired on a FACS X20 Fortessa (BD Bioscience) and analyzed with FlowJo
712 software (TreeStar).

713 **Statistical analysis.** All data were analyzed with one-way ANOVA test and Tukey post-
714 test unless otherwise noted and survival data were analyzed with Log-rank (Mantel-Cox)
715 test. Both tests were run using GraphPad Prism 6. *, $p \leq 0.05$; **, $p \leq 0.005$, ***, $p \leq$
716 0.0001. All errors bars are SEM and all center bars indicate means.

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745


746

747

748

749


750 **Supplementary figures**



751

752 **Fig. S1.** (related to figure 1). **a**, Creation of STING S365A and **b**, Δ CTT mice using
 753 CRISPR/Cas9. **c**, Bone marrow derived macrophages were stimulated for 6h and TNF- α
 754 was measured on the supernatant. **d**, Quantification of Fig.1d using LC3II/LC3I ratio. **e**,
 755 Colocalization of DNA and LC3 is increased in WT and S365A cells. Fluorescence
 756 images of primary macrophages transfected for 6h with Cy3-labeled DNA and LC3.
 757 Images were analyzed by an automated pipeline created on Perkin Elmer Harmony
 758 software for colocalization quantification (for more details refer to Methods). Scale bars
 759 are 50 μ m.

760




761

762 **Fig. S2.** (related to figure 2). Creation of IRF3 deficient mice using CRISPR/Cas9. **a**,
 763 CRISPR/Cas9 targeting strategy for IRF3. **b**, Sequencing of the targeted locus resulting
 764 in *Irf3*^{-/-} mutation. **c**, Immunoblot of MEFs for IRF3. **d**, Primary macrophages were
 765 transfected with c-di-GMP for 6h and relative expression of *Ifnb* was analyzed. **e**, Mice
 766 were aerosol infected with 400 CFU dose of *M. tuberculosis* (Erdman strain). Survival of
 767 infected mice. **f**, Bacterial burden from lungs at 21 days post infection. All mice except
 768 C57BL/6J WT were bred in-house. Representative results of four independent
 769 experiments. Error bars are SEM. Analyzed with one-way ANOVA and Tukey post-test.
 770 ns, not significant.


771

772




773
774
775
776
777
778
779
780
781

Fig. S3. (related to figure 3). Mice were intravenously infected with 1×10^6 PFU of HSV-1 (KOS strain). **a**, Viral titers in the liver at 6 days p.i. **b**, Relative expression of IFIT-1 **c**, TNF and **d**, IL-6 from brains at 3 days p.i. All mice except C57BL/6J WT were bred in-house. Representative results of five independent experiments. Error bars are SEM. Analyzed with one-way ANOVA and Tukey post-test. **, $p \leq 0.005$; ***, $p \leq 0.0001$. ns, not significant.



782
783
784
785
786
787
788

Fig. S4. (related to figure 4). Mice were ocular infected with 1×10^5 PFU of HSV-1 (strain 17). **a**, Viral titers from eyes washed at 2 days p.i. **b**, Relative expression of *viperin*. All mice except C57BL/6J WT were bred in-house. Representative results of three independent experiments. Error bars are SEM. Analyzed with one-way ANOVA and Tukey post-test. ns, not significant.




789

790 **Fig. S5.** (related to figure 4). Brain cells (neurons and astrocytes) were harvested from P0
 791 pups and infected with HSV-1 (KOS strain) at a MOI 1 for 6h and later were stained for
 792 LC3 and HSV-1. **a**, Quantification of colocalization of LC3-HSV-1 in neurons was
 793 performed and **b**, Viral titers from supernatants were collected 48h later and quantified by
 794 TCID50 assay. **c-d**, Same as a-b, in astrocytes. **e**, Cell lysates were collected at 4h post-
 795 infection and immunoblot for LC3 and β-actin was performed. Representative results
 796 from two independent experiments. Error bars are SEM. Analyzed with one-way
 797 ANOVA and Tukey post-test. *, $p \leq 0.05$. ns, not significant.

798

799



800
 801 **Fig. S6.** (related to figure 5). **a**, Mice were ocular infected with 1×10^5 PFU of HSV-1
 802 (strain 17) and viral titers measured in the brain 6 days p.i. **b**, BMDMs were transfected
 803 with 2'3'cGAMP for 6h and relative expression of *Ifnb* was analyzed. **c**, Mice were ocular
 804 infected with 1×10^5 PFU of HSV-1 (strain 17) and survival rate and **d**, viral titers
 805 measured in the brain stem 6 days p.i. All mice except C57BL/6J WT were bred in-
 806 house. Representative results of two independent experiments. Error bars are SEM.
 807 Analyzed with one-way ANOVA and Tukey post-test. *, $p \leq 0.05$; **, $p \leq 0.005$. ns, not
 808 significant.

809

810